JP2024540922A5 - - Google Patents
Info
- Publication number
- JP2024540922A5 JP2024540922A5 JP2024523525A JP2024523525A JP2024540922A5 JP 2024540922 A5 JP2024540922 A5 JP 2024540922A5 JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024540922 A5 JP2024540922 A5 JP 2024540922A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal according
- approximately
- solution
- powder
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163257073P | 2021-10-18 | 2021-10-18 | |
| US63/257,073 | 2021-10-18 | ||
| PCT/EP2022/078989 WO2023066941A1 (en) | 2021-10-18 | 2022-10-18 | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540922A JP2024540922A (ja) | 2024-11-06 |
| JP2024540922A5 true JP2024540922A5 (OSRAM) | 2025-10-27 |
Family
ID=84359608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523525A Pending JP2024540922A (ja) | 2021-10-18 | 2022-10-18 | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250066382A1 (OSRAM) |
| EP (1) | EP4419530A1 (OSRAM) |
| JP (1) | JP2024540922A (OSRAM) |
| CN (1) | CN118451082A (OSRAM) |
| WO (1) | WO2023066941A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| CN115279769A (zh) | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1591446E (pt) | 2003-01-29 | 2013-06-12 | Takeda Pharmaceutical | Compostos de tienopirimidina e sua utilização |
| PT3415517T (pt) | 2012-09-28 | 2022-05-13 | Takeda Pharmaceuticals Co | Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia |
| FI3263110T3 (fi) | 2015-02-26 | 2023-07-25 | Takeda Pharmaceuticals Co | Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita |
| EP3518932B1 (en) | 2016-09-30 | 2024-11-13 | Sumitomo Pharma Switzerland GmbH | Treatment of prostate cancer |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| EP3765464A1 (en) * | 2018-03-14 | 2021-01-20 | Teva Pharmaceuticals USA, Inc. | Solid state forms of relugolix |
| CN115279769A (zh) | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| EP4041738A1 (en) | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
-
2022
- 2022-10-18 EP EP22805826.9A patent/EP4419530A1/en active Pending
- 2022-10-18 WO PCT/EP2022/078989 patent/WO2023066941A1/en not_active Ceased
- 2022-10-18 JP JP2024523525A patent/JP2024540922A/ja active Pending
- 2022-10-18 CN CN202280069988.XA patent/CN118451082A/zh active Pending
-
2024
- 2024-04-16 US US18/636,642 patent/US20250066382A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551525A5 (OSRAM) | ||
| JP2022551316A5 (OSRAM) | ||
| KR100207360B1 (ko) | 이미다조[1,5,-a]퀸옥살린 | |
| JP4193949B2 (ja) | Ｉ型グリシン輸送阻害剤としての二環式［３．１．０］ヘテロアリールアミド | |
| ES2604542T3 (es) | Arilamidas con sustitución tetrazol | |
| US5629331A (en) | Process for the preparation of a tetrazole derivative in two crystalline forms and novel the crystalline forms thereof | |
| JP4740115B2 (ja) | 置換ピラゾール | |
| JP6240164B2 (ja) | ピロール誘導体の結晶及びその製造方法 | |
| US20090149505A1 (en) | Metabotropic Glutamate Receptor-Potentiating Isoindolones | |
| JP2024505063A5 (OSRAM) | ||
| JP2008514642A5 (OSRAM) | ||
| TW200838511A (en) | Novel pharmaceutical compounds | |
| TW200521115A (en) | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | |
| EP2118067A1 (en) | Nicotinic acetylcholine receptor modulators | |
| JPH06508370A (ja) | アンジオテンシン２拮抗活性を有する４−（１ｈ−ピロール−１−イル）イミダゾール | |
| JPH054391B2 (OSRAM) | ||
| CN112409293B (zh) | 苯并噻嗪酮化合物及其制备方法与作为抗结核药物的应用 | |
| JP2013542255A (ja) | ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素 | |
| CN101115755A (zh) | 作为mglur2拮抗剂的吡唑并-嘧啶衍生物 | |
| AU2004228121B2 (en) | 1,3,4-substituted pyrazoles for use as 5-HT receptor antagonists in the treatment of psychoses and neurological disorders | |
| JP2022533340A5 (OSRAM) | ||
| JP2024514090A5 (OSRAM) | ||
| WO2024193530A1 (zh) | 萘胺类线粒体自噬诱导剂的固体形式、其制备方法、药物组合物和用途 | |
| AU2004228119B2 (en) | Pyrazole compounds | |
| JP4385414B2 (ja) | アミド若しくはアミン誘導体 |